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Abstract
Background: Migraine is a common neurovascular disorder affecting 10 to 20 % of the world population
usually subdivided into migraine with auro (MA) and migraine without auro (MO). Homocysteine is involved in
the pathophysiology of a number of neurological disorders. Elevated levels of homocysteine in the plasma is
produced by the MTHFR gene rs 1801133 and rs 1801131 variants as well as the NNMT gene rs 694539 variant.
Methods: With the polymerase chain reaction-restriction fragment length polymorphism method developed
recently in our laboratory, we were able to show an association between the NNMT gene rs694539 variant and
migraine for the first time.
Results: Here we report the association of the Nicotinamide-N-methyltransferase gene (NNMT) rs694539 variant
with migraine in a case–control study of 433 patients with migraine and 229 healthy controls (χ2 = 6.076, P = 0.
048). After stratification, we were able only to show an association between the NNMT gene rs694539 variant
and female patients with migraine on the genotype and allelic levels. However there was no association in
male patients with migraine (χ2 = 1.054, P = 0.590).
Conclusions: Consequently our results clearly indicate that the NNMT gene rs694539 variant is a genetic risk
factor for migraine.
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Background
Migraine is a common and chronic neurovascular disorder
affecting approximately 10–20 % of the world population.
Clinically, It is sub-classified into migraine with aura (MA)
and migraine without aura (MO) accompanied by severe
recurrent headache attacks and associated symptoms such
as nausea, vomiting, photo- and phonophobia [1].
Homocysteine, a sulfur-containing amino acid derived
from the metabolism of methionine, has been implicated
in the pathophysiology of a variety of neurological disor-
ders such as migraine [1], essential tremor [2], stroke
[3], epilepsy [4]), schizophrenia [5, 6] and bipolar disor-
ders [7, 8]. 5,10-Methylenetetrahydrofolate reductase
(MTHFR), a key enzyme in the metabolism of folate cat-
alyzes the reduction of 5,10-methylenetetrahydrofolate
to 5-methyltetrahydrofolate, the predominant form of
folate and carbon donor for the remethylation of
homocysteine to metionine. Variants of the MTHFR
C677T (rs1801133) and A1298C (rs1801131) gene,
associated with significantly elevated plasma homocysteine
levels, were shown to be associated with migraine [9–21].
A meta-analysis has revealed that the MTHFR C677T
(rs1801133) variant is a genetic risk factor for migraine
[22]. Another enzyme implicated in one-carbon metabol-
ism is nicotinamide-N-methyltransferase (NNMT). Human
NNMT (EC 2.1.1.1), a cytoplasmic enzyme belonging to
Phase II conjugating enzymes, is reported to be expressed
in brain and other nervous tissues [23]. This gene is
16.703 bp in lenght on chromosome 11q23.1, having three
exons and two introns. NNMTcatalyzes the transfer of me-
thyl group from S-adenosyl-L-methionine (SAM) to nico-
tinamide (NA), thus creating 1-methylnicotinamide
(1MNA) and S-adenosylhomocysteine (SAH) which is later
hydrolyzed to homocysteine [24]. Homocysteine is one of
the key components of one-carbon metabolism. The
rs694539 NNMT variant, localized at the 114133419 bp
(G >A transition) is found to be significanly associated with
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elevated plasma homocysteine levels [25]. Elevated plasma
homocysteine levels were shown to be associated with an
increased risk of migraine in patients with the MTHFR
C677Tand A1298C polymorphisms [1, 11].
Recently, we showed that the MTHFR C677T and
A1298C variants were associated with migraine [1]. We
also wanted to reveal whether the rs694539 variant of
NNMT gene is associated with migraine. To do so we ana-
lyzed the allele and genotype frequencies of the NNMT




The subjects were 433 [351 (81 %) female; 82 (19 %)
male] patients with migraine and 229 [184 (80 %) fe-
male; 45 (20 %) male] healthy controls recruited from
the Istanbul University neurological clinic. The mean
age of migraine was 36.96 ± 14.863 years and controls
was 37.54 ± 16.403 years; age range for cases was 18–89
years, and for controls was 19–85 years. All patients
were diagnosed by an experienced neurologist using
International Classification of Headache Disorders
(ICHD) the third version (2013) [26]. The institutional
review board approved the present study and informed
consent was obtained from all subjects.
Genotyping
Genomic DNA was isolated from whole blood using the
salting-out procedure [27]. Genotypes of the subjects
were determined using a polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
method developed in our laboratory [28].
Statistical analysis
The Hardy-Weinberg equilibrium was verified for both
cases and controls. Differences between cases and con-
trols were determined using the χ2 test and Student’s t
test. Genotype and allele frequencies were calculated
using the χ2 test. Odds ratio (OR) and confidence inter-
val (95 % CI) were estimated using 2x2 cross-tabulation
and a binary logistic regression model for age and gen-
der. All statistical analyses were done using SPSS soft-
ware package version 21.0. The P value <0.05 % was
taken as significant.
Results and discussion
Here, we report an association between the rs694539 vari-
ant of NNMT gene with migraine for the first time (χ2 =
6.076, P = 0.048). The statistical power for all cases is 0.40
and for overall controls is 0.24 (Table 1). The individuals
with AA genotype confer a 3.8-fold increased risk for mi-
graine (χ2 = 5.372, P = 0.020, OR = 3.840, 95 % CI = 1.133–
13.013). Moreover, the G allele showed a 3.8-fold
protection against migraine (χ2 = 5.372, P = 0.020, OR =
0.260, 95 % CI = 0.077–0.883). Stratification analysis ac-
cording to gender revealed that there was an association
only in female patients with migraine. The female individ-
uals with the AA genotype revealed a 4.3-fold increased
risk for migraine (χ2 = 4.474, P = 0.034, OR = 4.346, 95 %
CI = 0.988–19.112). Similarly the individuals with the G
allele showed a 4.3-fold protection against migraine (χ =
4.474, P = 0.034, OR = 0.230, 95 % CI = 0.052–1.012).
However there was no association in male patients with
migraine (χ2 = 1.054, P = 0.590). All patients with migraine
and controls were in Hardy-Weinberg equilibrium (0.665
and 0.152, respectively) (Table 1).
Distributions of genotypes GG, GA and AA were 62.6,
32.6 and 4.8 % in overall patients with migraine and 68.1,
30.6 and 1.3 % in overall controls respectively (Table 1).
The frequencies of G allele were 78.87 % in overall cases
and 83.40 % in overall controls (Table 1). The frequencies
of A allele were 21.13 % in overall migraine patients and
16.59 % in overall controls (Table 1).
In the case control studies, a number of polymorphisms
have been shown to be associated with migraine. Plasma
urotensin-2 level and thr21met variant have been reported
to be associated with migraine [29]. It has been also shown
that the glutamatergic system is involved in the pathophysi-
ology of migraine [30]. DNA methylation status of RAMP1
gene has been shown to be associated with migraine [31].
Rs4379368 in the C7orf10 gene and rs13208321 in the
FHL5 gene have been reported to be associated with mi-
graine [32]. Genetic variants in the SYNE1 and TNF genes
have been shown to be related to menstrual migraine [33].
Recently genome-wide association studies have impli-
cated neuronal, vascular, metalloproteinase and pain
pathways in migraine [34].
More recently, GWASs have identified several single
nucleotide polymorphisms associated with migraine
pathophysiology [35–37] in genes and in regulatory re-
gions of genes implicated in epigenetic processes, includ-
ing MTDH, MEF2D and PRDM16. Metadherin (MTDH)
is shown to be associated with nuclear factor B (NFB) and
a HAT to promote the expression of NFB target genes
[38]. Myocyte enhancer factor 2D (MEF2D) can target
methyltransferase complexes to specific genes to make
them available for gene expression [39]. MEF2 has re-
cently been shown to be modulated through the gluco-
corticoid receptor [40], which may be one of the
mechanisms by which stress hormones affect the epige-
nome. Finally, PR domain containing 16 (PRDM16) is im-
plicated in positioning and removing specific chromatin
modifications at enhancer regions of Notch target genes
during olfactory neuron differentiation [41]. These studies
indicate that some of the migraine GWAS hits may con-
tribute to developing migraine through epigenetic alter-
ations at their target genes [42].
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Two GWAS have been carried out in migraine. One of
which concentrated mainly on patients with migraine with
auro and identified a single SNP in the MTDH gene [34].
The other study concentrated on migraine without auro and
identified six SNPs in the MEF2D, TGFBR2, PHACTR1,
ASTN2, TRPM8, and LRP1 gene associated with migraine
[37]. Recently a meta-analysis of studies on migraine
identified 12 SNPs significantly associated with migraine
[42]. Thus far 13 migraine susceptibility loci identified are
associated with neuronal (MTDH, LRP1, PRDM16, MEF2D,
ASTN2, PHACTR1, FHL5, MMP16), vascular (PHACTR1,
TGFBR2, c7orf10), metalloproteinase (MMP16, TSPAN2,
AJAP1) and pain (TRPM8) pathways. Most recently, GWAS
using 59 674 migraine cases and 316 078 controls identified
45 independent migraine associated SNPs mapping to 38
distinct genomic regions, 28 of which have not been
previously reported [43].
However, global DNA methylation has not been
reported in patients with migraine, elevated homocyst-
eine levels were revealed to be associated with cognitive
impairment [44, 45].
Conclusions
In summary, the role of the rs694539 variant of the
NNMT gene in migraine is unclear. Nonetheless,
through dysregulation of epigenetics and/or elevated
homocysteine levels or dysregulation of nicotinamide
levels may result in migraine or particularly through
Table 1 Genotype and Allele frequencies of the NNMT gene rs694539 variant in patients with Migraine and controls
Gene Cases Controls χ2 P-Values OR; 95 % CI
NNMT Rs694539 433 (100.0) 229 (100.0) 6.076 0.048
GG 271 (62.6) 156 (68.1) 2.005 0.157 0.783 (0.558–1.099)
GA 141 (32.6) 70 (30.6) 0.275 0.600 1.097 (0.776–1.550)
AA 21 (4.8) 3 (1.3) 5.372 0.020 3.840 (1.133–13.013)
Allele frequency
G Allele 683 (78.87) 382 (83.40) 5.372 0.020 0.260 (0.077–0.883)
A Allele 183 (21.13) 76 (16.59) 2.005 0.157 1.277 (0.910–1.794)
HWE(exact) 0.665 0.152





χ2 P-Values OR; 95 % CI
NNMT rs694539 351 (100.0) 184 (100.0) 5.650 0.059
GG 220 (62.7) 128 (69.6) 2.518 0.113 0.735 (0.502–1.076)
GA 115 (32.8) 54 (29.3) 0.652 0.419 1.173 (0.796–1.729)
AA 16 (4.6) 2 (1.1) 4.474 0.034 4.346 (0.988–19.112)
Allele frequency
G Allele 555 (79.06) 310 (84.24) 4.474 0.034 0.230 (0.052–1.012)
A Allele 147 (20.94) 58 (15.76) 2518 0.113 1.361 (0.930–1.993)
HWE(exact) 0.872 0.262





χ2 P-Values OR; 95 % CI
NNMT rs694539 82 (100.0) 45 (100.0) 1.054 0.590
GG 51 (62.2) 28 (62.2) 0.000 0.998 0.999 (0.472–2.114)
GA 26 (31.7) 16 (35.6) 0.194 0.659 0.842 (0.391–1.813)
AA 5 (6.1) 1 (2.2) 0.969 0.325 2.857 (0.323–25.244)
Allele frequency
G Allele 128 (78.05) 72 (80.00) 0.969 0.325 0.350 (0.040–3.092)
A allele 36 (21.95) 18 (20.00) 0.000 0.998 1.001 (0.473–2.119)
HWE(exact) 0.520 0.665
Statistical power 0.05 0.04
HWE Hardy-Weinberg Equilibrium
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vascular processes. Thus, our findings suggest that the
rs694539 variant of NNMT gene may play a role in the
etiopathology of migraine in the Turkish population
studied herein.
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